Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVE trial of salvage radiotherapy with apalutamide versus standard androgen deprivation after radical prostatectomy
2018-004365-13Phase 2Active
- Sponsor
- GZA
- Start
- Jan 2019
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apalutamide, leuprolide, triptorelin pamoate, degarelix and goserelin in prostate cancer (PCa) (2 arms), sponsored by GZA. Primary endpoint: EPIC-26 sexual domain score. Started Jan 2019; status: active.
02
Drugs
apalutamideleuprolidetriptorelin pamoatedegarelixgoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2018-004365-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004365-13.